Exosome-based Gaucher's disease Type-I and Gaucher's disease Type-III enzyme therapeutic - ILIAS Biologics
Latest Information Update: 28 Sep 2024
At a glance
- Originator ILIAS Biologics
- Class Enzymes; Exosome therapies; Gene therapies
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gaucher's disease type I; Gaucher's disease type III
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Gaucher's disease type I in South Korea
- 28 Sep 2024 No recent reports of development identified for research development in Gaucher's disease type III in South Korea
- 18 Aug 2020 Exosome-based Gaucher's disease Type-I and Gaucher's disease Type-III enzyme therapeutic - ILIAS Biologics is available for licensing as of 18 Aug 2020. http://iliasbio.com/eng/s1/s1_1.php